Eight genes were included in the study- ANKRD26, CEBPA, DDX41, ETV6, GATA2, MECOM, RUNX1, and SRP72. ANKRD26, GATA2, DDX41, CEBPA and RUNX1 are well-established myeloid malignancy predisposition genes, but the population prevalence is unknown since prior studies included cohorts ascertained on phenotype such as cancer registries or clinically identified cases series. This evidence concerns the gene GATA2 and cancer.